Is semaglutide the same as Ozempic or Wegovy?

So they contain the same drug, why do they have different names?

Pharmaceutical companies run separate clinical development programmes when they want a medicine approved for a new indication. Novo Nordisk first developed semaglutide as a once-weekly injectable treatment for type 2 diabetes and brought it to market as Ozempic. Later, higher doses were tested specifically in people living with obesity, without diabetes, across a large trial programme. The results were strong enough to secure a distinct licence, so Wegovy was born as a separate product, with its own approved dosing schedule, its own patient information leaflet, and a licence that covers weight management rather than blood-sugar control.

The practical upshot is this: the molecule is identical, but the products are legally and clinically distinct. In the UK, the MHRA licenses each medicine for its approved indication. Ozempic's licence covers type 2 diabetes. Wegovy's licence covers weight management in adults with a BMI of 30 or above, or 27 or above where a weight-related condition is present. Prescribing Ozempic to someone who wants to lose weight but does not have diabetes is off-label prescribing, not something a responsible UK prescriber does routinely, and not something any regulated online pharmacy should be offering. If you want to understand the practical differences in more depth, our page on semaglutide versus Wegovy works through the distinctions clearly.

The confusion is understandable. Both share a name (semaglutide) and both make news, and if you are wondering how the branded and peptide forms of semaglutide compare, our guide on semaglutide peptide versus Ozempic explains the key differences. But the licence is what governs safe, legal access.

Does Ozempic cause weight loss, and can I get it for that reason?

In clinical trials, Ozempic did produce weight loss as a side effect in people being treated for diabetes. That observation is part of what prompted the Wegovy trials in the first place. But clinical-trial observations and a licensed indication are not the same thing. The MHRA has been clear: GLP-1 medicines are not assessed for quick or cosmetic weight loss, and Ozempic is not licensed for weight management. The NHS medicines page for semaglutide sets this out plainly, distinguishing Ozempic and Wegovy by their respective indications.

There is a practical safety dimension here too. Wegovy's dosing schedule was designed with weight management patients in mind, starting at a lower dose to manage tolerability and reaching a maintenance level that the Wegovy trials showed to be effective. Ozempic's doses and titration steps were developed for a different patient group and a different clinical goal. Using the wrong product, at the wrong dose, without appropriate monitoring, creates avoidable risk, particularly around gastrointestinal side effects and, more seriously, the need to screen out contraindications before starting.

The short answer: weight loss seen with Ozempic is real, but obtaining it specifically to lose weight, outside a licensed and supervised pathway, is not appropriate UK clinical practice. If you are wondering how the two products compare head to head, our guide on Ozempic versus semaglutide for weight loss covers what the evidence actually shows.

What is Wegovy licensed for in the UK, and how does it work?

Wegovy is a once-weekly subcutaneous injection. It activates GLP-1 receptors, proteins involved in appetite regulation and the signalling that tells the brain a meal is underway. The result is reduced appetite, slower gastric emptying, and, for most people, a meaningful reduction in calorie intake without conscious restriction. In the STEP 1 trial, published in the New England Journal of Medicine, adults taking semaglutide 2.4mg alongside lifestyle changes lost an average of around 15% of their body weight over 68 weeks. An updated formulation (the 7.2mg Wegovy pen, approved by the MHRA on 14 April 2026) showed around 20.7% average weight loss in trials, narrowing the gap with tirzepatide.

Wegovy injection starts at 0.25mg and is titrated upward by the prescriber through several steps, roughly every four weeks, to the maintenance dose. Keeping the pen in the fridge door alongside everyday items is a practical prompt many patients find helpful, it becomes part of the weekly routine rather than something easily forgotten. For storage specifics and the exact titration schedule, the patient information leaflet is the right reference; your prescriber will also guide you through it.

The medicine carries a Black Triangle (▼) symbol, meaning it is subject to additional MHRA monitoring. NICE recommended Wegovy for NHS use under certain conditions (TA875), though access via specialist NHS services involves waiting lists that are often long. Privately, the picture is different: our Wegovy overview explains both routes and what to expect from each.

What weight-loss medicines are actually licensed and available in the UK?

Two injectable GLP-1 medicines are licensed for weight management in the UK: Wegovy (semaglutide, Novo Nordisk) and Mounjaro (tirzepatide, Eli Lilly). Mounjaro is a dual GIP and GLP-1 receptor agonist (the only medicine of its kind licensed in the UK) and SURMOUNT-5, a head-to-head trial published in 2025, found it produced greater average weight loss than semaglutide 2.4mg over 72 weeks. As of 11 June 2026, a third option exists: the Wegovy tablet, the first oral GLP-1 medicine approved for weight management in the UK. It uses oral semaglutide at a 25mg maintenance dose and requires no refrigeration, which makes it genuinely travel-friendly. NICE has not yet appraised it, so it is available privately at present.

Ozempic, Rybelsus (oral semaglutide for diabetes, at much lower doses), and Saxenda (liraglutide) each have specific licensed indications that do not cover straightforward weight management at the doses and in the contexts most readers have in mind. Orlistat, a different type of medicine that blocks fat absorption rather than acting on appetite, is also available. You can compare the two main prescription injection options on our Wegovy versus Ozempic page, or explore the full range of weight-loss treatment options we cover.

If you are considering starting treatment, a free consultation with one of our prescribers is the right first step. A real clinician reads every consultation the same day, there is no automated approval, just a proper clinical conversation about what is right for you. You can start your free consultation whenever you are ready. For questions about how Wegovy is priced privately, our Wegovy pricing page sets out what to expect.